Kotra Research Group is a multidisciplinary research group investigating at the intersection of medicinal chemistry, drug action, preformulations and pre/clinical studies. Kotra’s laboratory has successfully translated basic research into advanced preclinical and clinical studies. Over the past 20 years, Kotra’s lab has maintained high standards to conduct cutting edge research, including various regulatory clearances to conduct research with controlled substances such as medical cannabis.

Current research programs in Kotra’s laboratory include chemical/preclinical/clinical research on medical cannabis, cannabinoids and CNS-acting agents such as psychadelic molecules including on various cellular and organ systems, antivirals in organ transplant, disease-modifying therapies targeting multiple sclerosis and neurodegenerative disorders, discovery of small molecules targeting thrombocytopenia, development of treatment strategies for chronic rhinosinusitis (CRS), and clinical development of Kopakamal as an antimalarial agent. 

We are very proud of our collaborative network who are world-class, committed research groups to help advance the efforts towards meaningful clinical solutions.

How does a mixture of chemical compounds change receptor responses in the brain? How about compensatory mechanisms balancing minor aberrations due to chemical imbalance? How does neurodegeneration affect such chemical imbalances and compensatory mechanisms? What is the connection between mental health and neurodegeneration, and vice versa? We have a lot of interest and exciting projects in CNS acting agents, their role in neuroprotection and mental health, and developing novel therapeutics.

Connect with Dr. Kotra via Twitter and/or LinkedIn:

  • Twitter Clean Grey
  • LinkedIn Clean Grey

Check these out...

Kotra Research Group

Web UofT Pharmacy Logo.jpg
Krembil Relentless - email.jpg